Evidence map›Paper›PMID 37654616›Full record

ArticleFrontiers in pharmacology2023

Derivatives of 9-phosphorylated acridine as butyrylcholinesterase inhibitors with antioxidant activity and the ability to inhibit β-amyloid self-aggregation: potential therapeutic agents for Alzheimer's disease.

Galina F Makhaeva, Nadezhda V Kovaleva, Elena V Rudakova, Natalia P Boltneva, Sofya V Lushchekina, Tatiana Yu Astakhova, Elena N Timokhina, Olga G Serebryakova, Alexander V Shchepochkin, Maxim A Averkov and 9 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in pharmacology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
1.9field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 8 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors at 7 institutions in 2 countries.

Galina F MakhaevaInstitute of Physiologically Active Compounds at Federal Research Center of Problems of Chemical Physics and Medicinal Chemistry, Russian Academy of Sciences, Chernogolovka, Russia.
Nadezhda V KovalevaInstitute of Physiologically Active Compounds at Federal Research Center of Problems of Chemical Physics and Medicinal Chemistry, Russian Academy of Sciences, Chernogolovka, Russia.
Elena V RudakovaInstitute of Physiologically Active Compounds at Federal Research Center of Problems of Chemical Physics and Medicinal Chemistry, Russian Academy of Sciences, Chernogolovka, Russia.
Natalia P BoltnevaInstitute of Physiologically Active Compounds at Federal Research Center of Problems of Chemical Physics and Medicinal Chemistry, Russian Academy of Sciences, Chernogolovka, Russia.
Sofya V LushchekinaInstitute of Physiologically Active Compounds at Federal Research Center of Problems of Chemical Physics and Medicinal Chemistry, Russian Academy of Sciences, Chernogolovka, Russia.
Tatiana Yu AstakhovaEmanuel Institute of Biochemical Physics, Russian Academy of Sciences, Moscow, Russia.
Elena N TimokhinaEmanuel Institute of Biochemical Physics, Russian Academy of Sciences, Moscow, Russia.
Olga G SerebryakovaInstitute of Physiologically Active Compounds at Federal Research Center of Problems of Chemical Physics and Medicinal Chemistry, Russian Academy of Sciences, Chernogolovka, Russia.
Alexander V ShchepochkinInstitute of Organic Synthesis, Russian Academy of Sciences, Yekaterinburg, Russia.
Maxim A AverkovInstitute of Organic Synthesis, Russian Academy of Sciences, Yekaterinburg, Russia.
Irina A UtepovaInstitute of Organic Synthesis, Russian Academy of Sciences, Yekaterinburg, Russia.
Nadezhda S DeminaInstitute of Organic Synthesis, Russian Academy of Sciences, Yekaterinburg, Russia.
Eugene V RadchenkoInstitute of Physiologically Active Compounds at Federal Research Center of Problems of Chemical Physics and Medicinal Chemistry, Russian Academy of Sciences, Chernogolovka, Russia.
Vladimir A PalyulinInstitute of Physiologically Active Compounds at Federal Research Center of Problems of Chemical Physics and Medicinal Chemistry, Russian Academy of Sciences, Chernogolovka, Russia.
Vladimir P FisenkoDepartment of Pharmacology of the Institute of Biodesign and Complex System Modeling of Biomedical Science & Technology Park of Sechenov I.M., First Moscow State Medical University, Moscow, Russia.
Sergey O BachurinInstitute of Physiologically Active Compounds at Federal Research Center of Problems of Chemical Physics and Medicinal Chemistry, Russian Academy of Sciences, Chernogolovka, Russia.
Oleg N ChupakhinInstitute of Organic Synthesis, Russian Academy of Sciences, Yekaterinburg, Russia.
Valery N CharushinInstitute of Organic Synthesis, Russian Academy of Sciences, Yekaterinburg, Russia.
Rudy J RichardsonDepartment of Pharmacology of the Institute of Biodesign and Complex System Modeling of Biomedical Science & Technology Park of Sechenov I.M., First Moscow State Medical University, Moscow, Russia.
Institute of Physiologically Active Compounds · RUInstitute of Organic Synthesis · RUInstitute of Biochemical Physics NM Emanuel · RULomonosov Moscow State University · RUSechenov University · RUUniversity of Michigan–Ann Arbor · USUral Federal University · RU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We investigated the inhibitory activities of novel 9-phosphoryl-9,10-dihydroacridines and 9-phosphorylacridines against acetylcholinesterase (AChE), butyrylcholinesterase (BChE), and carboxylesterase (CES). We also studied the abilities of the new compounds to interfere with the self-aggregation of β-amyloid (Aβ

Indexed as

9-phosphoryl-9,10-dihydroacridines9-phosphorylacridinesacetylcholinesteraseAlzheimer’s diseasebutyrylcholinesterase

Identifiers

PMID37654616
PMCPMC10466253
OpenAlexW4385705936

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.